Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

ABSTRACT:

Background

Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.

Methods

From a Danish population-based nationwide cohort of HIV patients we identified the individuals who initiated a salvage regimen including raltegravir and a matched cohort of HIV-infected patients initiating HAART for the first time. We compared these two cohorts for virological suppression, gain in CD4 count, and time to first change of initial regimen.

Results

We identified 32 raltegravir patients and 64 HIV patients who initiated HAART for the first time in the period 1 January 2006 to 1 July 2009. The virological and immunological responses in the raltegravir patients were comparable to those seen in the control cohort. No

SUBMITTER: Engsig FN 

PROVIDER: S-EPMC2943192 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature